In 2023 alone, for example, the FDA greenlit elacestrant for ESR1-mutated BC, extended the approval of sacituzumab govitecan for HR-positive and Her2-negative BC, and approved the pan-AKT inhibitor capivasertib for HR-positive, Her2-negative advanced, or metastatic BC with one or more PIK3CA/AKT1/PTEN alterations [18]. This evidence concerns the gene ESR1 and breast cancer.